Clinical Trials Logo

Clinical Trial Summary

The study will assess the safety and efficacy of intravenous (10mg/kg) and subcutaneous (300mg) secukinumab in moderate to severe chronic plaque-type psoriasis who are partial responders to secukinumab.


Clinical Trial Description

n/a


Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT01412944
Study type Interventional
Source Novartis
Contact
Status Completed
Phase Phase 3
Start date December 2011
Completion date April 2013

See also
  Status Clinical Trial Phase
Withdrawn NCT01936688 - A Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous MK-3222 in Participants With Moderate-to-Severe Chronic Plaque Psoriasis (MK-3222-012) Phase 3
Completed NCT00763503 - Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of CD 2027 Spray in Adults With Plaque-type Psoriasis Phase 2
Completed NCT00773734 - Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate-to-Severe Plaque-Type Psoriasis (Core Study) Phase 2
Completed NCT01636687 - Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE) Phase 3
Completed NCT01258088 - Safety Study of Ointment for the Treatment of Plaque-type Psoriasis Phase 1
Completed NCT01132612 - AIN457 Regimen Finding Extension Study in Participants With Moderate to Severe Psoriasis Phase 2
Completed NCT00852761 - A Study to Evaluate the Efficacy and Tolerability of Topical Therapies for the Condition of Plaque-Type Psoriasis Phase 4
Completed NCT00625326 - Study of Dose-Effect of COL-121 Ointment in Patients With Plaque-Type Psoriasis Phase 2
Completed NCT00521339 - Apremilast Safety and PK Study in Recalcitrant Plaque Psoriasis Phase 2
Completed NCT01876875 - n-3 Polysaturated Fatty Acids-rich Diet in Psoriasis Phase 4